Sign in
Author
|
Conference
|
Journal
|
Organization
|
Year
|
DOI
Look for results that meet for the following criteria:
since
equal to
before
between
and
Search in all fields of study
Limit my searches in the following fields of study
Agriculture Science
Arts & Humanities
Biology
Chemistry
Computer Science
Economics & Business
Engineering
Environmental Sciences
Geosciences
Material Science
Mathematics
Medicine
Physics
Social Science
Multidisciplinary
Keywords
(5)
Acute Coronary Syndrome
Cost Effectiveness
National Health Service
United Kingdom
Glycoprotein
Subscribe
Academic
Publications
Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of non–ST-segment elevation acute coronary syndromes
Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of non–ST-segment elevation acute coronary synd
Edit
Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of non–ST-segment elevation acute coronary syndromes
BibTex
|
RIS
|
RefWorks
Download
Matthias Schwenkglenks
,
John E. Brazier
,
Thomas D. Szucs
,
Keith A. A. Fox
ObjectivesThis study sought to assess the cost-effectiveness of bivalirudin versus heparin plus
glycoprotein
IIb/IIIa inhibitor (GPI) in thienopyridine-treated non–ST-segment elevation
acute coronary syndrome
(NSTE-ACS) patients undergoing early or urgent invasive management, from a
United Kingdom
National Health Service
perspective.
Journal:
Value in Health - VALUE HEALTH
, vol. 14, no. 1, pp. 24-33, 2011
DOI:
10.1016/j.jval.2010.10.025
Cumulative
Annual
View Publication
The following links allow you to view full publications. These links are maintained by other sources not affiliated with Microsoft Academic Search.
(
www.sciencedirect.com
)